S204: SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY

• Jason Valent,
• Michaela Liedtke,
• Jeffrey Zonder,
• Maria Angelica Molina,
• Chandrasekhar Udata,
• Juliana Ianus,
• John Tripptree,
• Julia Catini,
• C Cristina Quarta

Affiliations

Jason Valent

1 Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States

Michaela Liedtke

2 Stanford University Medical Center, Palo Alto, United States

Jeffrey Zonder

3 Karmanos Cancer Center, Detroit, United States

Maria Angelica Molina

4 IQVIA, Durham, United States

Chandrasekhar Udata

5 Alexion, AstraZeneca Rare Disease, Boston, United States

Juliana Ianus

5 Alexion, AstraZeneca Rare Disease, Boston, United States

John Tripptree

5 Alexion, AstraZeneca Rare Disease, Boston, United States

Julia Catini

5 Alexion, AstraZeneca Rare Disease, Boston, United States

C Cristina Quarta

5 Alexion, AstraZeneca Rare Disease, Boston, United States